Zoetis (ZTS) : The consensus on Zoetis (ZTS) based on 8 analyst recommendation on the company stock is 1.75, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Zoetis (ZTS) : The consensus price target for Zoetis (ZTS) is $54.67 for the short term with a standard deviation of $5.99. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $62, however, the pessimist price target for the company is $49.
Also, In the latest statement by the brokerage house, Argus Research maintains its outlook on Zoetis (NYSE:ZTS). The current rating of the shares is Below Average, according to the research report released by the firm. The brokerage firm raises the price target from $54 per share to $58 per share. The rating by the firm was issued on September 9, 2016.
Zoetis (NYSE:ZTS): After opening at $50.71, the stock dipped to an intraday low of $50.2 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $50.93 and the buying power remained strong till the end. The stock closed at $50.72 for the day, a gain of 0.34% for the day session. The total traded volume was 3,331,049. The stocks close on the previous trading day was $50.55.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.